Literature DB >> 11580223

Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.

K R Chintalacharuvu1, L U Vuong, L A Loi, J W Larrick, S L Morrison.   

Abstract

Immunoglobulin (Ig) A and IgG are the principal immune effector molecules at mucosal surfaces and in blood, respectively. Mucosal IgA is polymeric and bound to secretory component, whereas serum IgG is monomeric. We have now produced IgA2/IgG1 hybrid antibodies that combine the properties of IgA and IgG. Antibodies with Calpha3 at the end of the IgG H chain resemble IgA and form polymers with J chain that bind the polymeric Ig receptor. Like IgG, the hybrid proteins activated complement and bound FcgammaRI and protein A. Though the hybrid proteins contained both Cgamma2 and Cgamma3, they have a short in vivo half-life. Surprisingly, this decreased half-life correlated with a higher avidity than that of IgG for murine FcRn. Interestingly, antibodies with Calpha1 replacing Cgamma1 were resistant to extremes of pH, suggesting that Calpha1 increases antibody stability. These results provide insights into engineering antibodies with novel combinations of effector functions. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580223     DOI: 10.1006/clim.2001.5083

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Authors:  M Jack Borrok; Nadia M Luheshi; Nurten Beyaz; Gareth C Davies; James W Legg; Herren Wu; William F Dall'Acqua; Ping Tsui
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Surface silver-doping of biocompatible glass to induce antibacterial properties. Part I: Massive glass.

Authors:  E Verné; M Miola; C Vitale Brovarone; M Cannas; S Gatti; G Fucale; G Maina; A Massé; S Di Nunzio
Journal:  J Mater Sci Mater Med       Date:  2008-11-06       Impact factor: 3.896

3.  Early stage reactivity and in vitro behavior of silica-based bioactive glasses and glass-ceramics.

Authors:  E Verné; O Bretcanu; C Balagna; C L Bianchi; M Cannas; S Gatti; C Vitale-Brovarone
Journal:  J Mater Sci Mater Med       Date:  2008-08-14       Impact factor: 3.896

Review 4.  The role of Fc receptors in HIV prevention and therapy.

Authors:  Austin W Boesch; Eric P Brown; Margaret E Ackerman
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

5.  Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.

Authors:  Bingyu Li; Lijun Xu; Fei Tao; Kun Xie; Zhiqiang Wu; You Li; Jie Li; Kaiming Chen; Chenyu Pi; Andrew Mendelsohn; James W Larrick; Hua Gu; Jianmin Fang
Journal:  Oncotarget       Date:  2017-06-13

Review 6.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

Review 7.  The present and future of immunocytokines for cancer treatment.

Authors:  Dennis Y Gout; Lotte S Groen; Marjolein van Egmond
Journal:  Cell Mol Life Sci       Date:  2022-09-06       Impact factor: 9.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.